DENVER–(BUSINESS WIRE)–#drugshortages—RISCS, Inc. announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance (EDSA) provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care. “We … [Read more…]
– Series B extension co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing Investors, including Pfizer Ventures, EcoR1 Capital and Sanofi Ventures. – – Proceeds to expand and diversify platform and pipeline to include mRNA and gene correction therapeutics for central nervous system, … [Read more…]
WINSTON-SALEM, N.C.–(BUSINESS WIRE)–#drugshortagemanagement–OrbitalRX announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care. “Drug shortages … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Contract Development & Manufacturing Market by Service, End User – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029. Following extensive secondary and primary … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Baculoviral IAP Repeat Containing Protein 5 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. This report provides in depth analysis on Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted pipeline … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Prefilled Syringes Global Market – Forecast To 2028” report has been added to ResearchAndMarkets.com’s offering. The prefilled syringes global market is expected to grow at a high single digit CAGR to reach $10,273.8 million by 2028. The prefilled syringes global market is categorized into various market segments based on the material, design, closure … [Read more…]
LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from … [Read more…]
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its resubmitted New Drug Application (NDA) for investigational palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Ipsen is seeking approval of palovarotene, an oral, selective … [Read more…]
SINGAPORE–(BUSINESS WIRE)–Now Health International, the award-winning international private medical insurance (IPMI) provider, has appointed Matt Pinckard as General Manager of its Singapore operations to lead the company’s business in the region. Reporting into Rob McIntyre, Now Health International’s Chief Distribution Officer, Pinckard will lead the company’s drive to introduce new innovations and technologies in the … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–CivaTech Oncology Inc., a leading developer of radioactive cancer therapeutics made a presentation regarding the CivaSheet® at the annual Biotechnology Innovation Organization (BIO) Conference June 14, 2022 in San Diego California. BIO International connects top research and early stage innovations with industry and investors. CivaTech Oncology’s CivaSheet® was supported in development and in … [Read more…]
